7 or/1-6 (empagliflozin* or Jardiance* or Jardianz* or Glimpacare* or Gibtulio* or Dzhardins* or Diacurimap* or Synjardy* 8 or Trijardy*).ti,ab,kf,ot,hw,rn,nm. [...] Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol? For Partial Yes: For Yes: Yes The authors state that they had a written protocol As for partial yes, plus the protocol should be registered Partial Yes or guide that included ALL the following. [...] Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review? For Yes: Yes There was no significant heterogeneity in the results No OR if heterogeneity was present the authors performed an investigation of sources of any heterogeneity in the results and discussed the impact of this on the results of the review 15. [...] • Consider the dose and schedule of the drug; mode of administration; background treatment; whether the drug is used as induction or maintenance treatment; whether the procedure or technique in the trials is the same as the procedure or technique that is of interest to the decision maker Are any relevant outcomes missing? No • Are the outcomes relevant to the decision maker? Are they relevant to •. [...] • Consider the dose and schedule of the drug; mode of administration; background treatment; whether the drug is used as induction or maintenance treatment; whether the procedure or technique in the trials is the same as the procedure or technique that is of interest to the decision maker Are any relevant outcomes missing? No • Are the outcomes relevant to the decision maker? Are they relevant to •.
- Pages
- 60
- Published in
- Canada
